Nanocarriers

Syphilis is a chronic and multi-stage infectious disease caused by Treponema pallidum, which has a rapid spread, resistance to immune responses, and chronic infection. This review is a synthesis of animal evidence to study the pathogenesis, clinical synergies, diagnostic plans, treatment plans, and epidemiological implications of the disease. The use of animal models, especially rabbits, has been critical in understanding the interaction of the host and pathogen, development of lesions, and immunological reactions. This research indicates the relative performance of the traditional and reverse screening algorithm, which shows that reverse screening has a better sensitivity during both early and latent periods, whereas the traditional approach is useful in monitoring active infection. The development of molecular diagnostics, particularly PCR and immunoassays, has improved early diagnosis and evaluation of the disease, whereas penicillin remains the most effective treatment despite the emerging resistance issues in other treatments. Additionally, experimental epidemiological research adds to the knowledge on the dynamics and persistence of transmission. Nevertheless, animal model limitations and issues with vaccine development because of immune evasion remain a major problem. The review highlights the necessity of a better experimental model, combined diagnostic, and novel treatment and vaccine options to improve the management of the disease and future research outcomes.

The oral route is still the most desirable route of drug delivery because of its ease of use, patient compliance and cost, but there is a major limitation regarding poor solubility of many therapeutic compounds in aqueous medium, therefore, this limits the oral delivery of the drug and clinical outcome. Solid lipid nanoparticles (SLNs) and nanostructured lipid carriers (NLCs), as well as self-emulsifying drug delivery systems (SEDDS), are the latest approaches to address these shortcomings. The nanoscales protect labile compounds against degraded by gastrointestinal system, increase solubility of drugs, and facilitate absorption via lymphatic system bypassing first-pass metabolism. Preclinical and animal experiments have demonstrated that SLNs give sustained release and gastrointestinal protection, NLCs give drug loading, stability and controlled release, and SEDDS gives dissolution, systemic exposure and lymphatic uptake. Another advantage of LNCs is better tissue distribution, extended circulation, ameliorated pharmacokinetic and pharmacodynamic activity. Regardless of their promise, such challenges as formulation stability, large scale production, interspecies translational differences, and excipient safety are critical factors. Altogether, LNCs provide a versatile and promising system of creation of effective patient-friendly oral preparations of drugs that are hardly soluble, and their possible clinical translation and specific treatment use have significant potential.

With an emphasis on formulation stability, safety, and clinical compatibility, the current study sought to create and assess stable parenteral emulsions for critical care medicine. Three batches of emulsions were made using pharmaceutical-grade lipids, emulsifiers, and isotonic agents, and the results were compared to control formulations. During a 90-day storage period at 4 °C, 25 °C, and 40 °C, physicochemical parameters such as droplet size, zeta potential, pH, and osmolarity were measured. While statistical analyses (ANOVA and Levene's Test) confirmed reproducibility and consistency across batches, sterility and endotoxin testing guaranteed microbial safety. According to the results, emulsions kept at 4 °C exhibited the best stability, whereas emulsions kept at higher temperatures experienced mild or rapid destabilization. Endotoxin levels were within pharmacopeial limits, and all batches remained sterile. The feasibility of creating stable and safe parenteral emulsions that can be administered intravenously to critically ill patients is highlighted in the study, along with the significance of appropriate storage conditions in maintaining formulation integrity.

Turmeric has been reported to reduce brain volume in mice models, TB positive and intestinal inflammation in mice models. The purpose of the study was to develop and optimize the curcumin-loaded nanostructured lipid carriers (NLCs) by hot high-pressure homogenization method in order to increase its oral bioavailability. The optimized formulation displayed the following properties, a particle size of 165.9 nm, and high entrapment efficiency, strong zeta potential providing physical stability. Sustained release was observed in vitro and in vivo pharmacokinetic analysis showed strongly increased systemic exposure and extended circulation half-life with respect to free curcumin. The study findings validate the findings that NLCs offer a potential delivery vehicle to facilitate enhanced bioavailability of poorly bioavailable bioactives and that NLCs have prospects in pharmaceutical and nutraceutical fields.

The need for alternative drug delivery methods that enhance patient compliance and therapeutic efficacy has been brought to light by the rising incidence of diabetes mellitus and the drawbacks of traditional oral therapy. In order to improve bioavailability by avoiding first-pass metabolism, this study concentrated on the formulation, development, and assessment of mucoadhesive buccal tablets of metformin hydrochloride. Using the direct compression method, five formulations (F1–F5) were created with different concentrations of the mucoadhesive polymers sodium alginate, HPMC, and carbopol 934. Physical characteristics, mucoadhesive strength, swelling index, surface pH, uniformity of drug content, and in-vitro drug release over an 8-hour period were all assessed for the tablets. With the best mechanical strength, the highest mucoadhesion (30.4 g), the most sustained drug release (93.7%), and controlled swelling (68%), formulation F5 outperformed the others. Significant variations between formulations were validated by statistical analysis employing ANOVA and Tukey HSD, confirming the influence of polymer concentration on drug release kinetics. According to the study's findings, mucoadhesive buccal tablets present a viable and patient-friendly substitute for the regulated administration of medications such as metformin hydrochloride, which are used to treat diabetes.

Cancer is a major global cause of death that requires new approaches to treatment outside the use of traditional chemotherapy, radiotherapy, and surgery. Nanomedicine, based on the application of nanoparticles (NPs) to targeted drug delivery, offers an exciting area of research for increased therapeutic benefits while reducing side effects. In this review, developments in nanotechnology-based drug delivery systems (DDSs) are discussed, focusing on their value in transcending multidrug resistance (MDR), improving bioavailability, and increasing the specificity of treatment. Several NP-based systems, such as liposomes, polymeric NPs, metal NPs, and quantum dots, are analyzed with respect to cancer therapy. Additionally, this paper addresses issues with clinical translation, including biocompatibility, toxicity, and regulatory issues. At last, upcoming trends and directions of future studies to optimize NP-based cancer treatments are presented.